Status:
TERMINATED
Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
Lead Sponsor:
University of Michigan Rogel Cancer Center
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be non-invasively identified using imaging phenotypes that identify regionally distinct areas of tumor with geneti...
Eligibility Criteria
Inclusion
- Suspected newly diagnosed or recurrent supratentorial glioblastoma eligible for surgical biopsy and/or resection
- Patients must be 18 years of age or older
- Study-specific informed consent approved for this purpose by the IRB of the University of Michigan
Exclusion
- Patients unable to undergo MRI
Key Trial Info
Start Date :
July 5 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 23 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03287063
Start Date
July 5 2018
End Date
March 23 2020
Last Update
July 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109